Evolus Expands HA Gel Rights as Toxin Growth Slows
Evolus locked up exclusive HA gel rights in every market where it sells its Jeuveau neurotoxin, a licensing push that outpaced a quarter in which revenue growth decelerated to 7%.
Evolus (EOLS), the aesthetics company behind the Jeuveau and Nuceiva neurotoxin franchise, expanded its dermal filler licensing deal with Symatese on August 4 to add exclusive Canadian, Australian and New Zealand rights to the Estyme hyaluronic acid gel collection, giving the company exclusive HA gel distribution in every territory where it markets its toxin.
The deal followed the July 8 announcement of a licensing agreement for IBSA's Profhilo skin-quality injectable, meaning Evolus struck two portfolio-expansion agreements in less than a month. Neither release disclosed financial terms, and the August 4 filing carried no revenue, margin or profitability figures, a departure from the full quarterly earnings reports the company issued on March 3 and May 4.
Evolus sized the opportunity behind the latest deal for the first time, pegging the Canadian, Australian and New Zealand neurotoxin and filler market at roughly $500 million annually, split about 60% neurotoxins and 40% fillers. The Estyme collection is expected to launch in those three markets in 2028, pending regulatory approval, a specific timeline it did not attach to the earlier Profhilo agreement covering the U.S. market.
The expansion push contrasts with the trajectory in Evolus's underlying business. First-quarter 2026 revenue rose 7% year-over-year to $73.1 million, a sharp deceleration from the 14% growth reported in the fourth quarter of 2025, when revenue reached $90.3 million. Toxin revenue fell to $66.4 million from $83.1 million sequentially, while HA gel revenue slipped to $6.7 million from $7.2 million, though its share of total revenue rose to 9.2% from 8.0% as toxin sales pulled back more sharply.
Profitability moved in the opposite direction of the top line. Adjusted EBITDA was positive for a second consecutive quarter at $0.6 million in the first quarter of 2026, compared with a $5.5 million loss in the prior-year period. GAAP operating results swung the other way, from operating income of $4.2 million in the fourth quarter of 2025 to an operating loss of $6.8 million in the first quarter of 2026, even as gross margin improved sequentially to 66.9% from 65.7%.
Customer metrics showed a similar split between deceleration and pockets of strength. Total purchasing accounts grew by nearly 500 in the first quarter of 2026, down from more than 600 added in the prior quarter, and total customers since launch topped 18,100, up from more than 17,700. Evolus Rewards membership additions also slowed, to nearly 75,000 from more than 76,000, trimming year-over-year growth to 27% from 30%. Evolysse-specific adoption moved the other way: customers purchasing the filler line rose to approximately 3,500 from more than 3,000, lifting U.S. account penetration above 60% from above 55%.
Evolus reaffirmed full-year 2026 revenue guidance of $327 million to $337 million on May 4, matching the range first issued alongside 2025 full-year results on March 3, when the company reported its sixth consecutive year of double-digit revenue growth at $297.2 million, up 12%. The August 4 release did not reference guidance.
The portfolio buildout leaves Evolus with a broader injectable lineup heading into a slower growth stretch for its core toxin business, with the newest additions to that lineup not expected to generate revenue for roughly two years.